Dr. Daniel Austin, D.O.
Family Medicine (Family Medicine Physician)
- Medicare participating
At a glance
- Medical school
- Philadelphia College of Osteopathic Medicine (2014)
- Years since graduation
- 12
- In the NPI registry since
- 2014
- Medicare patients seen, 2024
- 233
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2014Medical school: Philadelphia College of Osteopathic Medicine
- 2014Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
PA license OS018730
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- UPMC Presbyterian Shadyside Pittsburgh, PA
- Magee Womens Hospital of UPMC Health System Pittsburgh, PA
- St Clair Hospital Pittsburgh, PA
Medical groups
- Preferred Primary Care Physicians, Inc. (88 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 233
- Services billed
- 5,048
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 479 | 205 |
| Insertion of needle into vein for collection of blood sample | 352 | 183 |
| Blood test, basic group of blood chemicals (calcium, total) | 307 | 177 |
| Liver function blood test panel | 200 | 170 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test | 198 | 150 |
| Annual depression screening, 5 to 15 minutes | 187 | 187 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 184 | 184 |
| Blood test, lipids (cholesterol and triglycerides) | 176 | 168 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 119 | 37 |
| Blood test, thyroid stimulating hormone (tsh) | 106 | 78 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 10 industry-funded studies in 2025, from 5 companies. The companies reported $453,398 in research payments for these studies, mostly to the institutions running them.
- The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Eli Lilly and Company · Active, not recruiting · NCT06383390 - A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
Eli Lilly and Company · Active, not recruiting · NCT05556512 - A phase 3 placebocontrolled doubleblinded randomized study to evaluate the safety tolerability and immunogenicity of different vaccination schedules of 6VALENT ospabased lyme disease vaccine VLA15 in healthy adult par…
Pfizer Inc. - Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
Eli Lilly and Company · Active, not recruiting · NCT06297603 - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in p…
Boehringer Ingelheim Pharmaceuticals, Inc. - A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone
Eli Lilly and Company · Completed · NCT05971940 - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in p…
Boehringer Ingelheim Pharma GmbH & Co.kg - A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
Eli Lilly and Company · Completed · NCT05803421 - A phase 3 randomized doubleblind placebocontrolled study to assess the efficacy and safety of oncedaily oral danuglipron in adults with overweight or obesity
Pfizer Inc. - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in p…
Boehringer Ingelheim International GmbH
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.